Podium to Practice: ESMO® 2025 – Lung: PHAROS

Podium to Practice: ESMO® 2025 – Lung: PHAROS

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barbara Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Peter Ellis

Studies / Trials Discussed

1849MO – Updated overall survival analysis from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)

Studies/trials discussed:

1849MO – Updated overall survival analysis from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
Tagged